etrolizumab: Clinical Trials

8 trials of etrolizumab, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

6 completed, 2 terminated. 8 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	8	Completed 6, Terminated 2

Follow etrolizumab: new trials by email Literature Review of etrolizumab trials Research Report on etrolizumab

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 Etrolizumab - Crohn Disease	Phase 3	Terminated	Hoffmann-La Roche	790	2015-06-08	2024-12-02
A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease Etrolizumab, Placebo - Crohn Disease	Phase 3	Completed	Hoffmann-La Roche	1035	2015-03-20	2022-11-16
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors Etrolizumab, Infliximab, Placebo (IV) - Ulcerative Colitis	Phase 3	Completed	Hoffmann-La Roche	397	2014-12-24	2021-12-03
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors Adalimumab, Adalimumab Placebo, Etrolizumab - Ulcerative Colitis	Phase 3	Completed	Hoffmann-La Roche	358	2014-11-14	2021-07-23
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors Adalimumab, Adalimumab Placebo, Etrolizumab - Ulcerative Colitis	Phase 3	Completed	Hoffmann-La Roche	358	2014-11-04	2021-07-23
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies Etrolizumab - Ulcerative Colitis	Phase 3	Terminated	Hoffmann-La Roche	1822	2014-09-15	2024-10-23
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors Etrolizumab, Placebo - Colitis, Ulcerative	Phase 3	Completed	Hoffmann-La Roche	359	2014-08-12	2021-08-19
A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors Etrozulimab, Placebo - Ulcerative Colitis	Phase 3	Completed	Hoffmann-La Roche	609	2014-05-21	2021-08-13

Conditions studied

Sponsors

Countries

Results publications

NIH funding